Torrent Pharma

Which are the latest news on Torrent Pharma?

Why is Torrent Pharmaceuticals Ltd. falling/rising?

As of 05-Sep, Torrent Pharmaceuticals Ltd. is facing a stock price decline to 4,850.00, down -1.52%, with a total drop of -3.09% over the last two days. Despite strong year-to-date returns, recent trends show weakening investor interest and negative market sentiment.

As of 05-Sep, Torrent Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 4,850.00, which reflects a change of -74.7 (-1.52%). The stock has underperformed the sector today by -1.07% and has been on a consecutive downward trend for the last two days, with a total decline of -3.09% in this period. Additionally, the stock reached an intraday low of Rs 4822.25, marking a decrease of -2.08%.<BR><BR>The stock's performance over the past week shows a decline of -3.67%, while the benchmark Sensex has only decreased by -0.97%. Over the past month, Torrent Pharmaceuticals has also underperformed, with a drop of -3.58% compared to the Sensex's -2.44%. Although the stock has shown strong returns year-to-date (+26.25%) and over the past year (+34.86%), recent trends indicate a weakening in investor participation, as evidenced by a significant drop in delivery volume by -30.88% against the 5-day average.<BR><BR>Despite these recent challenges, the company maintains a high management efficiency with a return on capital employed (ROCE) of 21.88% and a low debt-to-EBITDA ratio of 3.30 times, which suggests a strong ability to service its debt. However, the current market sentiment appears to be negative, contributing to the stock's recent decline.

Who are in the management team of Torrent Pharma?

The management team of Torrent Pharma includes Sudhir Mehta (Chairman Emeritus), Samir Mehta (Executive Chairman), Jinesh Shah (Director of Operations), Aman Mehta (Whole Time Director), and Chintan Trivedi (Company Secretary). The board also features independent directors such as Shailesh Haribhakti and Ameera Shah, among others.

The management team of Torrent Pharma includes the following key members:<BR><BR>1. **Sudhir Mehta** - Chairman Emeritus<BR>2. **Samir Mehta** - Executive Chairman<BR>3. **Jinesh Shah** - Director (Operation)<BR>4. **Aman Mehta** - Whole Time Director<BR>5. **Chintan Trivedi** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- **Shailesh Haribhakti**<BR>- **H Khaitan**<BR>- **Ameera Shah**<BR>- **Nayantara Bali**<BR>- **Maurice Chagnaud**<BR>- **Manish Choksi**<BR><BR>This diverse team brings a wealth of experience and expertise to Torrent Pharma's operations and governance.

What does Torrent Pharma do?

Torrent Pharmaceuticals Ltd. is a major Indian pharmaceutical company established in 1959, specializing in chronic and sub-chronic therapeutic segments. As of June 2026, it reported net sales of ₹4,921 Cr and a net profit of ₹566 Cr, with a market cap of ₹188,904 Cr.

Overview:<BR>Torrent Pharmaceuticals Ltd. is a leading player in the Indian pharmaceutical sector, focusing on chronic and sub-chronic therapeutic segments within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Torrent Pharmaceuticals Ltd. was incorporated in the year 1959. The latest quarterly results reported are for June 2026, showcasing the company's ongoing performance in the market.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4,921 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 566 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 188,904 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 85.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.67%<BR>- Debt Equity: 1.55<BR>- Return on Equity: 26.24%<BR>- Price to Book: 22.83<BR><BR>Contact Details:<BR>Address: Torrent House, Off Ashram Road Ahmedabad Gujarat : 380009<BR>Tel: 91-79-26599000<BR>Email: investorservices@torrentpharma.com<BR>Website: http://www.torrentpharma.com

Who are the peers of the Torrent Pharma?

Torrent Pharma's peers include Sun Pharma, Divi's Lab, Zydus Lifesciences, Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma. Laurus Labs has the highest 1-year return at 122.69%, while Torrent Pharma's return is 39.88%, higher than Cipla's -10.92%.

Peers: The peers of Torrent Pharma are Sun Pharma.Inds., Divi's Lab., Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma, while Average management risk is found at Aurobindo Pharma. Growth is excellent for Sun Pharma.Inds., Zydus Lifesci., and Lupin, while Torrent Pharma, Dr Reddy's Labs, and Mankind Pharma show average growth. Below average growth is noted for Divi's Lab., Cipla, Laurus Labs, and Aurobindo Pharma, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 122.69%, while Cipla has the lowest at -10.92%. Torrent Pharma's 1-year return of 39.88% is significantly higher than Cipla's but lower than Laurus Labs'. Additionally, Dr Reddy's Labs and Cipla have negative six-month returns.

How big is Torrent Pharma?

As of 31st August, Torrent Pharmaceuticals Ltd. has a market capitalization of 188,904.00 Cr, with recent net sales of 15,723.00 Cr and a net profit of 2,156.00 Cr.

As of 31st August, Torrent Pharmaceuticals Ltd. has a market capitalization of 188,904.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Torrent Pharma reported Net Sales of 15,723.00 Cr and a Net Profit of 2,156.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 8,388.43 Cr and Total Assets valued at 43,613.69 Cr.

Are Torrent Pharmaceuticals Ltd. latest results good or bad?

Torrent Pharmaceuticals Ltd.'s latest Q1 FY27 results show strong net sales growth of 54.85% year-on-year, reaching ₹4,921 crores, but net profit only increased by 3.28% due to rising interest costs and depreciation, indicating a need for careful monitoring of profitability despite robust revenue performance.

Torrent Pharmaceuticals Ltd.'s latest results for Q1 FY27 present a mixed picture. On one hand, the company achieved impressive net sales of ₹4,921 crores, reflecting a remarkable year-on-year growth of 54.85% and a sequential increase of 17.25%. This growth is attributed largely to recent acquisitions, which have significantly boosted revenue.<BR><BR>However, the net profit growth was less impressive, with a modest increase of 3.28% year-on-year, rising to ₹566 crores. While this represents a substantial sequential improvement of 55.49% from the previous quarter, it highlights a disconnect between revenue and profit growth. The increase in net profit has been constrained by soaring interest costs, which surged by over 444% to ₹305 crores, and a significant rise in depreciation charges due to the recent acquisitions.<BR><BR>The operating margin improved to 34.42%, indicating effective cost management, but the profit after tax (PAT) margin contracted to 11.71%, down from 17.52% in the same quarter last year, reflecting the impact of increased financial charges.<BR><BR>Overall, while the top-line growth is strong and indicates robust operational performance, the bottom-line growth is concerning due to rising costs and debt levels. This situation suggests that while the company's revenue trajectory is promising, the financial health and profitability metrics warrant careful monitoring.

Should I buy, sell or hold Torrent Pharmaceuticals Ltd.?

When is the next results date for Torrent Pharmaceuticals Ltd.?

The next results date for Torrent Pharmaceuticals Ltd. is July 30, 2026.

The next results date for Torrent Pharmaceuticals Ltd. is scheduled for July 30, 2026.

Is Torrent Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bullish, supported by daily moving averages and weekly MACD, but tempered by mildly bearish monthly indicators and market indecision.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum and the weekly MACD also showing a bullish signal. However, the monthly MACD and KST are mildly bearish, suggesting some caution. Bollinger Bands are bullish on both weekly and monthly time frames, supporting the overall positive outlook. The lack of clear trends in Dow Theory and OBV indicates some indecision in the market. Overall, while there are bullish indicators, the presence of mildly bearish signals suggests a tempered bullish sentiment.

How has been the historical performance of Torrent Pharma?

Torrent Pharma has shown consistent growth in net sales and profits, with net sales increasing from INR 7,673 crore in March 2019 to INR 11,516 crore in March 2025, and profit after tax rising from INR 436 crore to INR 1,911 crore during the same period. The company also improved its operating profit margin to 32.88% and maintained a solid balance sheet.

Answer:<BR>The historical performance of Torrent Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Torrent Pharma's net sales have steadily increased from INR 7,673.00 crore in March 2019 to INR 11,516.00 crore in March 2025. The total operating income followed a similar trend, rising from INR 7,673.00 crore in March 2019 to INR 11,516.00 crore in March 2025. The company's operating profit (PBDIT) also saw growth, climbing from INR 2,041.00 crore in March 2019 to INR 3,744.00 crore in March 2025, reflecting an improving operating profit margin that reached 32.88% in March 2025. Profit before tax increased from INR 562.00 crore in March 2019 to INR 2,673.00 crore in March 2025, while profit after tax rose from INR 436.00 crore to INR 1,911.00 crore during the same period, resulting in a PAT margin of 16.89% in March 2025. On the balance sheet, total assets increased from INR 13,576.53 crore in March 2020 to INR 14,395.59 crore in March 2025, while total liabilities decreased from INR 14,505.45 crore in March 2024 to INR 14,395.59 crore in March 2025. The cash flow from operating activities showed a positive trend, reaching INR 2,585.00 crore in March 2025, although the net cash flow reflected an outflow of INR 261.00 crore in the same year. Overall, Torrent Pharma has demonstrated strong growth in revenue and profitability, alongside a solid balance sheet position.

Who are the top shareholders of the Torrent Pharma?

The top shareholders of Torrent Pharma include Torrent Investments Limited with 68.31%, followed by institutional investors such as mutual funds at 5.03% and foreign institutional investors at 16.31%. The highest public shareholder is NPS Trust at 1.8%, while individual investors hold 4.51% of the shares, with no pledged promoter holdings reported.

The top shareholders of Torrent Pharma are primarily the promoters, with Torrent Investments Limited holding the largest share at 68.31%. Additionally, institutional investors play a significant role, with 38 mutual funds collectively holding 5.03% and 819 foreign institutional investors (FIIs) holding 16.31%. The highest public shareholder is NPS Trust, which holds 1.8%, while individual investors account for 4.51% of the shares. There are no pledged promoter holdings reported.

Is Torrent Pharma overvalued or undervalued?

As of January 12, 2024, Torrent Pharma is considered very expensive and overvalued, with a PE Ratio of 55.29 and an EV to EBITDA of 29.34, significantly higher than its peers like Sun Pharma and Cipla, despite a strong historical performance.

As of 12 January 2024, Torrent Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market positioning. The company is currently considered overvalued. Key ratios include a PE Ratio of 55.29, an EV to EBITDA of 29.34, and a PEG Ratio of 2.63, all of which are substantially higher than industry norms.<BR><BR>In comparison to its peers, Torrent Pharma's valuation metrics stand out unfavorably; for instance, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla boasts a more attractive PE of 22.99 and an EV to EBITDA of 15.93. The elevated ratios suggest that Torrent Pharma is priced at a premium compared to its competitors, reinforcing the conclusion of overvaluation. Despite a strong historical performance, including a 10.86% return over the past year compared to the Sensex's 7.65%, the current valuation does not align with its financial fundamentals.

What is the bonus history of the Torrent Pharma?

Torrent Pharmaceuticals has issued bonuses to shareholders, with the most recent being a 1:1 bonus on July 8, 2022, and a previous 1:1 bonus on July 23, 2013. This practice demonstrates the company's commitment to rewarding its shareholders.

Torrent Pharmaceuticals has a history of issuing bonuses to its shareholders. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of July 8, 2022, and a record date of July 11, 2022. Prior to that, the company also issued a 1:1 bonus on July 23, 2013, with a record date of July 24, 2013. This consistent practice of bonus issues reflects the company's commitment to rewarding its shareholders.

Has Torrent Pharma declared dividend?

Yes, Torrent Pharmaceuticals Ltd. has declared a 520% dividend, amounting to ₹26 per share, with an ex-date of January 31, 2025. The company has shown strong total returns over various periods, particularly in the long term.

Torrent Pharmaceuticals Ltd. has declared a 520% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 520%<BR>- Amount per share: 26 per share<BR>- Ex-date: 31 Jan 25<BR><BR>Dividend Yield: 1.02%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -5.18%, the dividend return was 0.78%, resulting in a total return of -4.4%.<BR><BR>For the 1-year period, the price return was 13.48%, the dividend return was 1.12%, leading to a total return of 14.6%.<BR><BR>Over the 2-year period, the price return was 76.44%, the dividend return was 3.34%, culminating in a total return of 79.78%.<BR><BR>In the 3-year period, the price return was 127.44%, the dividend return was 5.39%, resulting in a total return of 132.83%.<BR><BR>For the 4-year period, the price return was 124.57%, the dividend return was 7.42%, leading to a total return of 131.99%.<BR><BR>In the 5-year period, the price return was 166.6%, the dividend return was 12.25%, culminating in a total return of 178.85%.<BR><BR>Overall, Torrent Pharmaceuticals has declared a substantial dividend, and the total returns over various periods indicate strong performance, particularly in the longer term, suggesting a positive outlook for investors.